-
SU5416 (Semaxanib): Reliable Assay Workflows
2026-09-02
This scenario-based guide helps researchers use SU5416 (Semaxanib), SKU A3847, in endothelial proliferation, viability, cytotoxicity, and angiogenesis workflows. It covers concentration design, DMSO compatibility, interpretation of VEGFR2-dependent effects, HIF1α-related confounding, and practical vendor-selection criteria.
-
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide
2026-09-02
The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat IgG primary antibodies in ICC/IF, frozen or paraffin IHC, flow cytometry, and fluorescence-compatible ELISA. It should not be used as a universal secondary antibody for non-goat primaries, non-IgG targets, or unvalidated live-cell workflows.
-
Doxorubicin: From DNA Damage to Cardiac Insight
2026-09-01
Doxorubicin hydrochloride and Adriamycin HCl remain valuable translational tools because the same mechanisms that drive tumor-cell killing can expose cardiac liabilities. This thought-leadership guide connects DNA damage, energy stress, apoptosis, and the emerging ATF4–CSE–H2S cardioprotection hypothesis to more decision-ready cancer and cardiotoxicity workflows.
-
Clarithromycin and CYP3A: Translational Design
2026-09-01
A mechanistic and strategic guide to using Clarithromycin as a CYP3A inhibitor in drug-drug interaction research, pharmacokinetic studies, and cardiovascular translation. The article explains how to design interpretable experiments, position CYP3A-independent comparators, and avoid overextending in vitro findings into clinical conclusions.
-
CSBTA Pharmacokinetics in MASH Mice
2026-08-31
The reference study integrates pharmacokinetics, tissue distribution, transporter assays, microsomal metabolism, and PXR-related analysis to explain how MASH alters exposure to three major Corydalis saxicola Bunting total alkaloids. Its central finding is that HFHCD-induced disease and repeated dosing increase systemic and hepatic exposure, providing a mechanistic basis for dose variability in MASLD/MASH treatment.
-
2-Hydroxypropyl-β-cyclodextrin Workflow Guide
2026-08-31
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide for handling poorly water-soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. This guide focuses on pharmaceutical solubility improvement, drug formulation excipient workflows, and biochemical formulation studies; it does not establish therapeutic efficacy or support unrelated applications.
-
Protease Inhibitor Cocktail for Plant Assays
2026-08-30
Discover how a Protease Inhibitor Cocktail supports protein stability in plant extracts while improving interpretation of symbiosis and flavonoid-signaling assays. This guide connects inhibitor selection, EDTA-free chemistry, and the NSP2–MYB40 research framework to practical workflow decisions.
-
ARID1A-Linked Melanoma Resistance Networks
2026-08-29
The reference study integrates transcriptional, proteomic, and signaling data to define how ARID1A loss rewires melanoma responses to BRAF/MAPK inhibition. Its identification of PRKD1, JUN, and NCK1 as resistance-associated network nodes connects persistent kinase activity with immune-related and extracellular-matrix changes, providing a mechanistic framework for cancer biology and metastatic melanoma research.
-
Chloramphenicol for Plasmid Transfer Assays
2026-08-28
Use Chloramphenicol as a controlled selection tool for plasmid maintenance, conjugation screens, and resistance-gene workflow validation. This guide connects practical assay design with recent evidence on carbapenemase-encoding gene transmission in Enterobacter cloacae while emphasizing orthogonal confirmation and troubleshooting.
-
Iron Stress Reprograms Enterocyte Metabolism
2026-08-28
Navazesh and Ji used paired iron-deficiency and iron-excess models in IPEC-J2 enterocytes to show that iron imbalance produces distinct transcriptional, inflammatory, and metabolic states. Their integration of time-course gene analysis, LPS challenge, and untargeted metabolomics provides a useful framework for studying intestinal iron homeostasis and metabolic resilience.
-
Triptolide (PG490): Mechanisms and Research Use
2026-08-27
Triptolide, also known as PG490, is a nanomolar-potency natural product used in cancer research, immunology, and inflammation studies. Its reported actions include IL-2 suppression, NF-κB transcriptional inhibition, CDK7-associated RNA polymerase II loss, matrix metalloproteinase reduction, and apoptosis induction.
-
InstaBlue Protein Stain Solution Workflow
2026-08-27
Build a rapid, solvent-free gel workflow for antibody expression checks, variant comparison, and MS-oriented band selection. InstaBlue Protein Stain Solution delivers visible Coomassie contrast in minutes while preserving a practical path to downstream protein characterization.
-
Meropenem: Mechanism and Infection Research
2026-08-26
Meropenem is a β-lactam antibiotic carbapenem that inhibits bacterial cell-wall synthesis through penicillin-binding proteins. Its broad in vitro activity supports Gram-negative bacterial infection models, while recent carbapenem-resistance data show why susceptibility and resistance-gene testing must accompany experimental use.
-
Nanozyme Liposomes for Facial Nerve Repair
2026-08-26
A 2026 Materials Today Bio study developed NP41-modified, ROS-responsive liposomes that co-deliver Ferrostatin-1 and Mn-doped CeO2 nanozymes to suppress oxidative injury and ferroptosis after facial nerve damage. In mice, this strategy improved the inflammatory microenvironment, Schwann cell preservation, remyelination, and functional recovery, while providing a useful framework for tissue-targeted ferroptosis modulation.
-
SmD2 Acetylation and PARP Inhibitor Sensitivity in HCC
2026-08-25
This Nature Communications study identifies the spliceosome core protein SmD2 as an acetylation-regulated determinant of BRCA1/FANC cassette-exon usage, DNA-repair capacity, and PARP inhibitor response in hepatocellular carcinoma. Its preclinical data support a mechanistic rationale for combining HDAC-axis intervention with PARP inhibition, while highlighting the need for HCC-specific validation and biomarker development.